Pulsatile inhibition of PI3K converts immune suppression by Tregs and M2-TAM to anti-tumor immune response in animal models insensitive or resistant to the monotherapies of PI3K and checkpoint inhibitors

被引：1
|
作者：
Glaeske, Sarah [1 ]
Huebner, Franziska [1 ]
Anurin, Anna [1 ]
Janzer, Andreas [1 ]
Zitzmann-Kolbe, Sabine [1 ]
Paul, Juliane [1 ]
Glaeske, Katja [1 ]
Berndt, Sandra [1 ]
Mumberg, Dominik [1 ]
Gorjanacz, Matyas [1 ]
Ziegelbauer, Karl [1 ]
Kreft, Bertolt [1 ]
Liu, Ningshu [1 ]
机构：
[1] Bayer AG, Berlin, Germany
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-LB-123
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-123
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PI3Kγ INHIBITION POTENTIATES IMMUNE CHECKPOINT BLOCKADE
    不详
    CANCER DISCOVERY, 2017, 7 (01) : 9 - 9
  • [2] Inhibition of PI3K promotes anti-tumor immune responses to Mantle Cell Lymphoma
    Shissler, Susannah Claire
    Webb, Tonya J.
    JOURNAL OF IMMUNOLOGY, 2019, 202 (01):
  • [3] Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors
    Smith, Aleisha M.
    Xiong, Jessie
    Hunter, Lucas
    Jordan, Jamie
    Clark, Kelly
    Darr, David B.
    Norman, Sharpless
    Perou, Charles M.
    Kim, William Y.
    CANCER RESEARCH, 2015, 75
  • [4] The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors
    Zhang, Zhizhu
    Richmond, Ann
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2021, 8
  • [5] Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
    Yan, Chi
    Yang, Jinming
    Saleh, Nabil
    Chen, Sheau-Chiann
    Ayers, Gregory D.
    Abramson, Vandana G.
    Mayer, Ingrid A.
    Richmond, Ann
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (10)
  • [6] Control of tumor immune suppression by macrophage PI3Kγ regulated pathways.
    Varner, Judith A.
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (04) : 24 - 24
  • [7] Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses
    Simon Heller
    Sarah Glaeske
    Katja Gluske
    Juliane Paul
    Annika Böhme
    Andreas Janzer
    Helge Gottfried Roider
    Anna Montebaur
    Barbara Nicke
    Ralf Lesche
    Oliver von Ahsen
    Oliver Politz
    Ningshu Liu
    Mátyás Gorjánácz
    Clinical and Experimental Medicine, 2023, 23 : 5445 - 5461
  • [8] Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses
    Heller, Simon
    Glaeske, Sarah
    Gluske, Katja
    Paul, Juliane
    Boehme, Annika
    Janzer, Andreas
    Roider, Helge Gottfried
    Montebaur, Anna
    Nicke, Barbara
    Lesche, Ralf
    von Ahsen, Oliver
    Politz, Oliver
    Liu, Ningshu
    Gorjanacz, Matyas
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (08) : 5445 - 5461
  • [9] SYNERGISTIC ANTITUMOR ACTIVITY OF PI3K INHIBITION AND IMMUNE CHECKPOINT BLOCKADE IN BLADDER CANCER
    D'Andrea, Vincent
    Pan, Chong-Xian
    Garisto, Juan D.
    JOURNAL OF UROLOGY, 2023, 209 : E187 - E187
  • [10] HER3 inhibition potentiates anti-tumor effects of PI3K inhibitors in pre-clinical models of HNSCC
    Davis, Kara S.
    Khan, Nayel
    Kemp, Carolyn
    Kulkarni, Sucheta
    Alvarado, Diego
    LaVallee, Theresa
    Grandis, Jennifer R.
    Duvvuri, Umamaheswar
    CANCER RESEARCH, 2015, 75
12345